Bavarian Nordic A/S has agreed a contract with an “undisclosed” European country for the supply of its smallpox vaccine, Imvanex, after a growing number of cases of monkeypox were confirmed in the UK and Portugal.
The non-replicating vaccine has been approved for both smallpox and monkeypox in the US and Canada, while in Europe it is authorized only for smallpox “but has previously been provided for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?